The Journal of Neuroscience, July 22, 2009, 29(29):9321-9329; doi:10.1523/JNEUROSCI.4736-08.2009
Previous Article | Next Article 
Neurobiology of Disease
Decreased Brain-Derived Neurotrophic Factor Depends on Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease
Shiyong Peng,1
Diego J. Garzon,1
Monica Marchese,1
William Klein,2,3
Stephen D. Ginsberg,4
Beverly M. Francis,5,6
Howard T. J. Mount,5,6
Elliott J. Mufson,7
Ahmad Salehi,8 and
Margaret Fahnestock1
1Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario L8N 3Z5, Canada, 2Institute for Neuroscience, Northwestern University, Evanston, Illinois 60611, 3Department of Neurobiology and Physiology, Northwestern University, Evanston, Illinois 60208, 4Nathan Kline Institute, New York University School of Medicine, Orangeburg, New York 10962, 5Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario M5S 3H2, Canada, 6Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada, 7Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, and 8Department of Neurology, Stanford University, Stanford, California 94305
Correspondence should be addressed to Dr. Margaret Fahnestock, Department of Psychiatry and Behavioural Neurosciences, McMaster University, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada. E-mail: Email: fahnest{at}mcmaster.ca
Downregulation of brain-derived neurotrophic factor (BDNF) in the cortex occurs early in the progression of Alzheimer's disease (AD). Since BDNF plays a critical role in neuronal survival, synaptic plasticity, and memory, BDNF reduction may contribute to synaptic and cellular loss and memory deficits characteristic of AD. In vitro evidence suggests that amyloid-β (Aβ) contributes to BDNF downregulation in AD, but the specific Aβ aggregation state responsible for this downregulation in vivo is unknown. In the present study, we examined cortical levels of BDNF mRNA in three different transgenic AD mouse models harboring mutations in APP resulting in Aβ overproduction, and in a genetic mouse model of Down syndrome. Two of the three Aβ transgenic strains (APPNLh and TgCRND8) exhibited significantly decreased cortical BDNF mRNA levels compared with wild-type mice, whereas neither the other strain (APPswe/PS-1) nor the Down syndrome mouse model (Ts65Dn) was affected. Only APPNLh and TgCRND8 mice expressed high Aβ42/Aβ40 ratios and larger SDS-stable Aβ oligomers (
115 kDa). TgCRND8 mice exhibited downregulation of BDNF transcripts III and IV; transcript IV is also downregulated in AD. Furthermore, in all transgenic mouse strains, there was a correlation between levels of large oligomers, Aβ42/Aβ40, and severity of BDNF decrease. These data show that the amount and species of Aβ vary among transgenic mouse models of AD and are negatively correlated with BDNF levels. These findings also suggest that the effect of Aβ on decreased BDNF expression is specific to the aggregation state of Aβ and is dependent on large oligomers.
Received Sept. 29, 2008;
revised April 26, 2009;
accepted May 14, 2009.
Correspondence should be addressed to Dr. Margaret Fahnestock, Department of Psychiatry and Behavioural Neurosciences, McMaster University, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada. E-mail: Email: fahnest{at}mcmaster.ca